Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24

Sarepta price target lowered to $160 from $267 at H.C. Wainwright

H.C. Wainwright analyst Debjit Chattopadhyay said the CRL from the FDA for golodirsen "came as a rude surprise" and was "seemingly arbitrary." The potential for renal issues, which was not reported in the clinical program, could be weighing on the FDA's decision, or the CRL could be a signal of a more circumspect agency, which would require clinical evidence to align with surrogate markers to justify accelerated approval, said the analyst, who can't say which it might be. In the absence of more information, he is eliminating golodirsen and casimersen from his model and lowering his price target on Sarepta shares to $160 from $267. If there is indeed a change of mindset at the agency, it could be a multi-year wait for exon-53 and -45 amenable subjects, added the analyst, who keeps a Buy rating on Sarepta.

SRPT Sarepta
$120.16

-4.81 (-3.85%)

08/16/19
CHDN
08/16/19
UPGRADE
Target $10
CHDN
Buy
Chardan upgrades Solid Biosciences to Buy after IGNITE DMD trial update
As previously reported, Chardan analyst Gbolahan Amusa upgraded Solid Biosciences (SLDB) to Buy from Neutral after the company provided an update on the IGNITE DMD phase I/II study of its AAV-based gene therapy, SGT-001, for Duchenne muscular dystrophy. The company's update and trial protocol changes suggest to the analyst that concerns on SGT-001 may be addressable, which may mean Solid is still positioned to address potential manufacturing constraints in the AAV-based gene therapy DMD space. Amusa noted that Sarepta Therapeutics (SRPT) utilizes less-scalable adherent processes that may limit supply and may mean Sarepta's product could cost more per patient to manufacture. Amusa raised the price target on Solid shares to $10 from $7.50.
08/19/19
LEER
08/19/19
UPGRADE
Target $15
LEER
Outperform
Solid Biosciences upgraded to Outperform with $15 target at SVB Leerink
As previously reported, SVB Leerink analyst Joseph Schwartz upgraded Solid Biosciences (SLDB) to Outperform from Market Perform after reassessing the protocol amendments and enrollment progress communicated by the company for its Phase 1/2 IGNITE-DMD trial. He believes much of the concerns that have weighed on the stock are baked-in at this point and continues to believe that Solid's scalable manufacturing "could be an underappreciated X-factor" that could potentially help it catch-up to the leader in the DMD space, Sarepta (SRPT). Schwartz raised his price target on Solid shares to $15 from $8.
08/20/19
JMPS
08/20/19
NO CHANGE
Target $270
JMPS
Outperform
Sarepta price target lowered to $270 from $275 at JMP Securities
JMP Securities analyst Liisa Bayko lowered her price target on Sarepta to $270 after the company's disclosure of an FDA a Complete Response Letter regarding the deficiencies of its golodirsen, but keeps her Outperform rating and sees the weakness as an opportunity to buy more share. The analyst notes that while approval was largely expected, golodirsen only represented about $6 in stock value. Bayko adds that she still expects golodirsen to launch, but not until 2021 vs. prior forecast of Q3 of this year, also lowering the probability of success to 60% from 70%.
08/20/19
PIPR
08/20/19
NO CHANGE
Target $185
PIPR
Overweight
Sarepta price target lowered to $185 from $208 at Piper Jaffray
Piper Jaffray analyst Danielle Brill lowered her price target for Sarepta to $185 from $208 after the company's disclosure of an FDA a Complete Response Letter regarding the deficiencies of its golodirsen, but kept her Overweight rating. Brill tells investors in a research note that "it certainly feels like there may be more" behind the FDA's decision to issue a CRL than the reasons cited, and says "it does not appear to be something that can be [easily] reconciled." Brill says she is still bullish for gene-tx, but notes more downside risk without support from golodirsen and casimersen.

TODAY'S FREE FLY STORIES

MDR

McDermott

$1.66

-0.5 (-23.15%)

13:19
09/19/19
09/19
13:19
09/19/19
13:19
Periodicals
McDermott CEO cancels appearance after hiring adviser, Bloomberg reports »

McDermott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/19/19
09/19
13:17
09/19/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/19/19
09/19
13:16
09/19/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHUN

Phunware

$1.97

0.21 (11.93%)

13:10
09/19/19
09/19
13:10
09/19/19
13:10
Hot Stocks
Phunware jumps over 17% after saying it will launch IEO of Phun tokens »

Earlier on Thursday,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MACK

Merrimack

$5.58

0.22 (4.10%)

13:10
09/19/19
09/19
13:10
09/19/19
13:10
Hot Stocks
Newtyn Management discloses 8.8% stake in Merrimack Pharmaceuticals »

Noah Levy's Newtyn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

13:10
09/19/19
09/19
13:10
09/19/19
13:10
General news
Treasury Action: the markets are likely to settle down, awaiting the next big thing »

Treasury Action: the…

MAR

Marriott

$130.22

0.07 (0.05%)

13:08
09/19/19
09/19
13:08
09/19/19
13:08
Hot Stocks
Marriott announces agreement to bring Ritz-Carlton brand to Montenegro »

Marriott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:06
09/19/19
09/19
13:06
09/19/19
13:06
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

13:06
09/19/19
09/19
13:06
09/19/19
13:06
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

WBA

Walgreens Boots Alliance

$54.79

0.365 (0.67%)

, GOOGL

Alphabet Class A

$1,237.98

5.02 (0.41%)

13:06
09/19/19
09/19
13:06
09/19/19
13:06
Hot Stocks
Walgreens to test on-demand drone delivery service with Wing »

Walgreens (WBA) and Wing,…

WBA

Walgreens Boots Alliance

$54.79

0.365 (0.67%)

GOOGL

Alphabet Class A

$1,237.98

5.02 (0.41%)

GOOG

Alphabet

$1,238.09

5.46 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

GOOG

Alphabet

$1,238.27

5.64 (0.46%)

, GOOGL

Alphabet Class A

$1,238.02

5.06 (0.41%)

13:05
09/19/19
09/19
13:05
09/19/19
13:05
Hot Stocks
Wing partners with FedEx Express, Walgreens to launch drone delivery service »

Wing Aviation LLC, an…

GOOG

Alphabet

$1,238.27

5.64 (0.46%)

GOOGL

Alphabet Class A

$1,238.02

5.06 (0.41%)

FDX

FedEx

$150.71

-0.2 (-0.13%)

WBA

Walgreens Boots Alliance

$54.80

0.38 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 30

    Sep

  • 01

    Oct

  • 27

    Oct

  • 13

    Nov

  • 17

    Dec

EROS

Eros International

$3.43

0.88 (34.51%)

13:04
09/19/19
09/19
13:04
09/19/19
13:04
Hot Stocks
Eros teams with Microsoft on 'next generation' online video platform »

Earlier today, Eros…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$41.47

0.41 (1.00%)

13:04
09/19/19
09/19
13:04
09/19/19
13:04
Hot Stocks
GlaxoSmithKline granted orphan status for biliary cholangitis treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

GRUB

GrubHub

$61.36

-2.42 (-3.79%)

12:55
09/19/19
09/19
12:55
09/19/19
12:55
Options
GrubHub put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
09/19/19
09/19
12:55
09/19/19
12:55
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

XGN

Exagen

$0.00

(0.00%)

12:54
09/19/19
09/19
12:54
09/19/19
12:54
Syndicate
Breaking Syndicate news story on Exagen »

Exagen opens at $16.80,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

XGN

Exagen

$0.00

(0.00%)

12:50
09/19/19
09/19
12:50
09/19/19
12:50
Syndicate
Breaking Syndicate news story on Exagen »

Exagen indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CAIXY

CaixaBank

$0.00

(0.00%)

12:46
09/19/19
09/19
12:46
09/19/19
12:46
Periodicals
France's CNP, CaixaBank near $1.7B insurance pact, Reuters reports »

France's CNP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$19.00

0.06 (0.32%)

12:45
09/19/19
09/19
12:45
09/19/19
12:45
Options
iQiyi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$62.58

-1.2 (-1.88%)

, UBER

Uber

$34.10

-0.14 (-0.41%)

12:43
09/19/19
09/19
12:43
09/19/19
12:43
Hot Stocks
GrubHub sinks after Jim Chanos announces short position »

Shares of GrubHub (GRUB)…

GRUB

GrubHub

$62.58

-1.2 (-1.88%)

UBER

Uber

$34.10

-0.14 (-0.41%)

DVA

DaVita

$59.91

-1.39 (-2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MACK

Merrimack

$5.32

-0.04 (-0.75%)

12:38
09/19/19
09/19
12:38
09/19/19
12:38
Hot Stocks
Western Standard discloses 6.3% stake in Merrimack Pharmaceuticals »

Eric Andersen's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

PLAN

Anaplan

$50.67

-0.13 (-0.26%)

12:35
09/19/19
09/19
12:35
09/19/19
12:35
Options
Anaplan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 16

    Oct

HWBK

Hawthorn Bancshares

$23.20

0.01 (0.04%)

12:34
09/19/19
09/19
12:34
09/19/19
12:34
Hot Stocks
Hawthorn Bancshares authorizes $5M for common stock repurchase program »

Hawthorn Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$63.75

-0.03 (-0.05%)

, UBER

Uber

$34.26

0.02 (0.06%)

12:33
09/19/19
09/19
12:33
09/19/19
12:33
Hot Stocks
Chanos not positive on any company with food delivery business »

Jim Chanos, founder of…

GRUB

GrubHub

$63.75

-0.03 (-0.05%)

UBER

Uber

$34.26

0.02 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$71.88

0.3 (0.42%)

, MO

Altria Group

$40.22

-0.62 (-1.52%)

12:33
09/19/19
09/19
12:33
09/19/19
12:33
Hot Stocks
CDC says vaping illnesses increase to 530 probable cases »

The CDC said in a…

PM

Philip Morris

$71.88

0.3 (0.42%)

MO

Altria Group

$40.22

-0.62 (-1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.